GT BIOPHARMA INC (GTBP) Stock Price, Quote, News and Overview
NASDAQ:GTBP - Nasdaq - US36254L3087 - Common Stock - Currency: USD
GTBP Quote, Performance and Key Statistics
2.84
+0.02 (+0.71%)
The current stock price of GTBP is 2.84 USD. In the past month the price increased by 26.79%. In the past year, price decreased by -1.73%.
GTBP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.61 | 337.52B | ||
| AMGN | AMGEN INC | 14.22 | 158.74B | ||
| GILD | GILEAD SCIENCES INC | 14.21 | 136.81B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 116.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.94 | 57.14B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 40.16B | ||
| ARGX | ARGENX SE - ADR | 100.5 | 35.29B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.89 | 29.17B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.62B | ||
| NTRA | NATERA INC | N/A | 22.58B | ||
| BIIB | BIOGEN INC | 8.26 | 19.14B | ||
| INSM | INSMED INC | N/A | 17.98B |
Related stock screener links
About GTBP
Company Profile
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The company is headquartered in San Francisco, California and currently employs 1 full-time employees. The company went IPO on 2013-10-22. The firm is focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary Tri-specific Killer Engager (TriKE) natural killer (NK) cell engager platform. Its TriKE platform is designed to harness and enhance the cancer-killing abilities of a patient’s immune system’s natural killer cells. Its product candidate pipeline includes GTB-3550, GTB-3650, GTB-5550, GTB-7550, GTB-6550, GTB-1050, and other product candidates. GTB-3550 is a TriKE comprised of two single-chain variable fragments (scFv) composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. GTB-3650 is a TriKE which targets CD33 on the surface of myeloid leukemias. The firm also has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.
Company Info
GT BIOPHARMA INC
505 Montgomery Street, 10Th Floor
San Francisco CALIFORNIA 90212 US
CEO: Anthony J. Cataldo
Employees: 2
Phone: 18003049888
GT BIOPHARMA INC / GTBP FAQ
What is the stock price of GT BIOPHARMA INC today?
The current stock price of GTBP is 2.84 USD. The price increased by 0.71% in the last trading session.
What is the ticker symbol for GT BIOPHARMA INC stock?
The exchange symbol of GT BIOPHARMA INC is GTBP and it is listed on the Nasdaq exchange.
On which exchange is GTBP stock listed?
GTBP stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for GT BIOPHARMA INC stock?
7 analysts have analysed GTBP and the average price target is 11.22 USD. This implies a price increase of 295.07% is expected in the next year compared to the current price of 2.84. Check the GT BIOPHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is GT BIOPHARMA INC worth?
GT BIOPHARMA INC (GTBP) has a market capitalization of 7.36M USD. This makes GTBP a Nano Cap stock.
How many employees does GT BIOPHARMA INC have?
GT BIOPHARMA INC (GTBP) currently has 2 employees.
What are the support and resistance levels for GT BIOPHARMA INC (GTBP) stock?
GT BIOPHARMA INC (GTBP) has a support level at 2.84 and a resistance level at 2.9. Check the full technical report for a detailed analysis of GTBP support and resistance levels.
Should I buy GT BIOPHARMA INC (GTBP) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of GTBP, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of GTBP, evaluating the profitability, health, valuation and growth aspects
- GT BIOPHARMA INC (GTBP) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- GT BIOPHARMA INC (GTBP) Sales and EPS estimates to see what analysts future expectations are.
- GT BIOPHARMA INC (GTBP) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- GT BIOPHARMA INC (GTBP) Insider and Institutional Ownership to learn about the owners and their transactions.
- GT BIOPHARMA INC (GTBP) Stock Chart to make your own analysis
- GT BIOPHARMA INC (GTBP) Latest news and press-releases to stay up to date.
Does GT BIOPHARMA INC (GTBP) stock pay dividends?
GTBP does not pay a dividend.
When does GT BIOPHARMA INC (GTBP) report earnings?
GT BIOPHARMA INC (GTBP) will report earnings on 2025-08-12.
What is the Price/Earnings (PE) ratio of GT BIOPHARMA INC (GTBP)?
GT BIOPHARMA INC (GTBP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.7).
What is the Short Interest ratio of GT BIOPHARMA INC (GTBP) stock?
The outstanding short interest for GT BIOPHARMA INC (GTBP) is 1.95% of its float. Check the ownership tab for more information on the GTBP short interest.
GTBP Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to GTBP. When comparing the yearly performance of all stocks, GTBP turns out to be only a medium performer in the overall market: it outperformed 57.68% of all stocks.
GTBP Financial Highlights
Over the last trailing twelve months GTBP reported a non-GAAP Earnings per Share(EPS) of -5.7. The EPS increased by 19.08% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -439.13% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
GTBP Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to GTBP. The Buy consensus is the average rating of analysts ratings from 7 analysts.